Press Release

New PREMUROSA project will improve the treatment of musculoskeletal disorders 

A group of international partners from Italy, Finland, Portugal, Ireland, Latvia, Serbia and Switzerland launched an EU funded project Precision medicine for musculoskeletal regeneration, prosthetics, and active ageing – PREMUROSA. The 3-years programme main objective is to train a new generation of tissue engineering scientists from multiple European countries to develop new technologies and new therapies for musculoskeletal disorders. 

Musculoskeletal diseases are reported to affect roughly half of those over 60, strongly impacting the quality of life and posing a significant burden on healthcare and welfare systems. Treatment of musculoskeletal disorders is currently based either on prosthetic or regenerative surgical procedures, often involving medical device implantation, compromising the effectiveness of treatments. 

A significant improvement could be achieved by precision medicine, specifically designed on patient’s individual characteristics. This requires new and highly skilled professionals who will develop new strategies for translating tissue engineering innovations into useful information to customise therapies, taking into account the characteristics of each patient. 

The project aims at training a new generation of scientists with an integrated vision of the whole value chain in musculoskeletal regeneration technologies and able to boost the necessary innovations to achieve precision principles in developing innovative devices and optimized clinical applications. 

A total of 13 students from the field of medical and health sciences, clinical medicine, surgery and surgical procedure will be selected to take part in the interdisciplinary project and earned their PhD degrees. Students will be hosted by a member of a European consortium of universities, research institutions and companies in Italy, Switzerland, Portugal, Finland, Latvia, Ireland and Serbia. 

Young researchers will gain advanced knowledge and skills, through an innovative combination of academic, industrial and clinical experience and training. They will benefit from an excellent scientific environment, up-date technologies and supervision by international leaders in the field. 

The successful implementation of PREMUROSA will not only set the ground for innovative PhD training but will also contribute in meeting important SOCIAL CHALLENGES, such as optimisation of clinical choices and therefore improvement of quality of life of patients and reduction of healthcare system costs. Moreover, industrial competitiveness will be substantially boosted due to medical devices optimisation and the development of new products in the project. 

The consortium comprises elevenEuropean partner institutions led by the University of Eastern Piedmont (Alessandria, Novara and Vercelli, Italy), and several non-academic partners and companies specialising in the biomedical field. 

Kickoff meeting

Among the 11 partner organisations are: University of Eastern Piedmont (Alessandria, Novara and Vercelli, Italy), Rizzoli Orthopaedic Institute (Bologna, Italy), Aalto University Foundation (Aalto, Finland), AO Research Institute Davos (Davos, Switzerland), Riga Technical University (Riga, Latvia), Faculty of Technology and Metallurgy, University of Belgrade (Belgrade, Serbia), INEB—National Institute of Biomedical Engineering, University of Porto (Porto, Portugal), Polytechnic University of Turin (Turin, Italy), EnginSoft SpA (Trento, Italy), Tampere University of Technology, (Tampere, Finland), National University of Ireland Galway (Galway, Ireland). 

PREMUROSA is part of the Marie Sklodowska-Curie Innovative Training Network – European Joint Doctorates programme, funded by the European research and innovation programme Horizon 2020. The project aims to train a new generation of creative, entrepreneurial and innovative early-stage researchers, able to face current and future challenges and to convert knowledge and ideas into products and services for economic and social benefit.